{
  "symbol": "REGN",
  "year": 2023,
  "period": "Q2",
  "curated_text": "Symbol: REGN. Year: 2023. Period: Q2. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Company, Libtayo, Dupixent, the Antibody Collaboration, LCA, Regeneron, the IO Collaboration, Bayer Collaboration Revenue, Total Bayer, Bayer, Roche Collaboration Revenue Three Months Ended June 30, Roche, Change Research, Change Direct, Linvoseltamab, Reimbursement of research and, the Sanofi Antibody Collaboration, FDA. Context excerpt: competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits in connection with commercialization of antibodies $ 751.1 $ 496.6 $ 1,387.6 $ 911.9 Sales-based milestones earned \u2014 \u2014 \u2014 50.0 Reimbursement for manufacturing of commercial supplies (a) 192.6 145.5 354.5 306.3 Other \u2014 28.9 \u2014 28.9 Total Antibody 943.7 671.0 1,742.1 1,297.1 Total Immuno-oncology \u2014 6.5 \u2014 11.3 Total Sanofi collaboration revenue $ 943.7 $ 677.5 $ 1,742.1 $ 1,308.4 (a) Corresponding costs incurred by the Company in connection with such production is recorded within Cost of collaborati",
  "competition_summary": [
    {
      "competitor": "Company",
      "mentions": 4,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Libtayo",
      "mentions": 3,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Dupixent",
      "mentions": 4,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "the Antibody Collaboration",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "LCA",
      "mentions": 2,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Regeneron",
      "mentions": 10,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "the IO Collaboration",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Bayer Collaboration Revenue",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Total Bayer",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Bayer",
      "mentions": 5,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Roche Collaboration Revenue Three Months Ended June 30",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Roche",
      "mentions": 2,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Change Research",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Change Direct",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Linvoseltamab",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "Reimbursement of research and",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "the Sanofi Antibody Collaboration",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    },
    {
      "competitor": "FDA",
      "mentions": 1,
      "context": "competition. As described in \"Collaboration, License, and Other Agreements - Sanofi - Immuno-Oncology \" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2023 2022 2023 2022 Antibody: Regeneron's share of profits"
    }
  ]
}